Effect of governor vessel moxibustion (GVM) therapy with mild to moderate psoriasis: A randomized clinical trial
Dan Sun,Wen-Ya Feng,Jing-Kang Mou,Lu Chen,Yi-Ding Zhao,Xiao-Ning Yan,Wen-Bin Li
DOI: https://doi.org/10.1097/md.0000000000035726
IF: 1.6
2024-02-10
Medicine
Abstract:Psoriasis (PS) is a recurring and refractory skin illness that can affect the scalp, face, nails, genitals, limbs, and even the entire body, causing scaly erythema, thin film phenomena, and spotty hemorrhaging. PS impacts the physical and mental health of patients, especially when it is associated with cardiovascular disease, obesity, mental and emotional issues, or other diseases. [ 1–3 ] Both the occurrence and development of PS are related to heredity, immunity, infection, metabolism, and other factors. [ 4 ] Immune dysfunction and interactions in the inflammatory cytokine network contribute significantly to PS pathogenesis and thus form an essential theoretical foundation for the prevention and treatment of the disorder. Targeted drugs such as monoclonal antibodies against interleukin 17 (IL-17) and tumor necrosis factor-alpha (TNF-α, as well as traditional drugs such as retinoic acid, glucocorticoids, calcineurin inhibitors are often not acceptable to PS patients due to the risk of side effects. Although many of these drugs are initially effective. [ 5 ] Methotrexate, ciclosporin, vitamin D3 derivatives, retinoids, and glucocorticoids can cause recurrence, irritation, and rebound after withdrawal. They also have anti-inflammatory or immunosuppressive effects on keratinocytes. Targeted biologics are complicated by adverse effects, drug resistance, and price. It is thus essential to find a safe, effective, and affordable PS treatment.
medicine, general & internal